Market Intelligence, Clinical Progress, and High-Purity Reagents for Acute Hepatic Porphyria (AHP) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALAS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALAS1 Recombinant Protein (Full-length, PLP-binding domain). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by SEC-MALS. | View ALAS1 Products |
| Gene Delivery | ALAS1 Promise-ORF / Lentivirus. Full-length ORF for stable HepG2 cell lines. Native mitochondrial localization signal retained. | View ALAS1 Products |
| Benchmark Ab | Anti-ALAS1 Recombinant Antibody (Research Grade Detection Clone). For Western Blot and ELISA validation. Recombinant rabbit IgG, sequence defined. | View ALAS1 Products |
| Validator | ALAS1 siRNA Set. For knockdown verification and assay positive control. Validated >80% mRNA reduction in HepG2 cells. | View ALAS1 Products |
| Related Target A | ALAS2 (Erythroid-Specific Isoform). Essential for off-target selectivity counter-screening; inhibition linked to sideroblastic anemia. | View ALAS2 Products |
| Related Target B | ASGPR (ASGR1/ASGR2). Essential receptor for liver-targeted GalNAc-siRNA delivery. | View ASGPR Products |
| Related Target C | HMBS (Porphobilinogen Deaminase). Downstream heme synthesis enzyme; complementary target for porphyria pathway modulation. | View HMBS Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ALAS1 vs ALAS2 Isoform Selectivity | Human ALAS1 & ALAS2 proteins available with >95% purity; Sequence Verified for PLP-binding domain fidelity. |
| Intracellular Delivery Verification (GalNAc-siRNA) | Sequence Verified ASGPR antigens (HEK293-expressed for native glycosylation) for GalNAc-conjugate binding assays. |
| Mitochondrial Active Conformation & Enzymatic Activity | HEK293-expressed full-length protein ensuring native folding and catalytic activity for succinyl-CoA/glycine condensation assays. |
| Lack of Standardization in Knockdown Assays | Validated siRNA included for specificity checks and transcript baseline normalization. Anti-ALAS1 detection antibody for orthogonal target engagement verification. |
| Preclinical Species Translation | Human/Mouse/Cyno ALAS1 proteins (>95% purity) for cross-species activity correlation. |
Live ALAS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALAS1 therapeutics is intensely focused on RNA interference, with Alnylam's givosiran validating the target in acute hepatic porphyria (AHP). ALAS1 (5'-aminolevulinate synthase 1) is the rate-limiting enzyme in hepatic heme biosynthesis. In AHP, induction of ALAS1 leads to toxic accumulation of intermediates (ALA and PBG). As first-generation siRNA therapies establish clinical proof-of-concept, the next wave of R&D is targeting ultra-durable knockdown, oral small-molecule allosteric inhibitors, and CRISPR-based gene editing to achieve functional cures. A critical safety frontier is achieving absolute selectivity over the erythroid isoform ALAS2 to avoid hematologic toxicity. Additionally, second-generation RNAi and small molecule allosteric inhibitors entering Phase II require sophisticated enzymatic assays capable of detecting subtle differences in mitochondrial uptake and catalytic inhibition kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / RNAi | Alnylam Pharmaceuticals (Givosiran/Givlaari) | Acute Hepatic Porphyria (AHP), Porphyria Cutanea Tarda (PCT) | GalNAc Delivery Assay (Need high-purity ASGPR ECD); Cellular Knockdown & Heme Precursor Quantification (Need Lentivirus & siRNA) |
| Small Molecule Inhibitor | Various Discovery Stage / Preclinical Biotech | AHP, Variegate Porphyria, Metabolic Disorders | Enzymatic Selectivity Assay (Need high-purity ALAS1 vs ALAS2 proteins >95% purity) |
| Antisense Oligonucleotide (ASO) | Ionis Pharmaceuticals | Acute Intermittent Porphyria (AIP) | Specificity vs ALAS2 (Ortholog protein panels); Target Engagement Validation (Need detection antibodies) |
| Gene Therapy / CRISPR | Academic / Early Biotech | Severe Genetic Porphyrias (AHP) | Knockout Validation (Need sequence-verified benchmark antibodies); Stable Expression Cell Lines (Lentivirus delivery systems) |